Drug General Information (ID: DDIG21EXLF)
Drug Name			Tranylcypromine		Drug Info		Tetrabenazine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antidepressants				Nephropathic Cystinosis Therapy
Structure

Mechanism of Tranylcypromine-Tetrabenazine Interaction (Severity Level: Major)
Additive hypertensive effects Click to Show/Hide Mechanism Graph
Drug Name		Tranylcypromine				Tetrabenazine
Mechanism		Hypertensive effects				Hypertensive effects
Key Mechanism Factor 1
		Factor Name		Hypertensive effects
		Factor Description		Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
Mechanism Description		Additive hypertensive effects by the combination of Tranylcypromine and Tetrabenazine

Recommended Action
Management		Concurrent administration of tetrabenazine and deutetrabenazine with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with either tetrabenazine or deutetrabenazine, and vice versa.

References
1	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
2	Product Information. Nitoman (tetrabenazine). Cambridge Laboratories Ltd, Wallsend, Tyne & Wear, .
3	Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.